Samsung Bioepis

Psoriasis impacts a patient’s everyday life and well-being, affecting their interests, relationships, and aspirations. This #WorldPsoriasisDay, let’s look beyond the visible skin symptoms to see the person. #LookBeyondMySkin

Today, we announced our Q3 2026 financial results. Milestone-excluded product sales and operating profit grew 4.1% and 21.3% YoY, respectively. 🔗 Read the full press release: shorturl.at/In5L0

#GRxBiosims2026, hosted by the @AccessibleMeds, runs November 2-4, 2026, in Maryland. Our VP and Head of Regulatory Strategy and Policy, Gillian Woollett, will speak on expanding patient access to safe, quality-assured medicines. 🔗 Register here: shorturl.at/ddG92

We joined global industry leaders and regulatory authority representatives at the Festival of Biologics Basel 2026. Our Senior Manager, Regulatory Strategy and Policy, External Operations, Joseph P. Park presented and joined a panel discussion on biosimilar development.

Supply reliability can affect product availability, provider confidence, and purchasing decisions in the biosimilar market. Explore the current state of the biosimilar supply chain in the US in our Q4 2026 Biosimilar Market Report: shorturl.at/rvkYr

Our first novel antibody-drug conjugate candidate has been granted Fast Track designation by the U.S. Food and Drug Administration. For more details, read the press release: shorturl.at/lOIzW

Most decision-makers know that biosimilars deliver significant healthcare cost savings. But what about their social value? Explore the broader impact of biosimilars on society and the economy in the latest edition of our Re:Access newsletter: shorturl.at/XTWwe

Today, we announced a landmark 10-year agreement with Bahiafarma and Bionovis to expand access to critical rare disease treatments in Latin America. 🔗 Read the press release: shorturl.at/wCzPz

🌎 IGBA’s 7th annual Global Biosimilars Week kicks off today, under the theme “Realizing the Global Value of Biosimilars,” running through October 24. ✒️ Register for the webinar on October 21 here: shorturl.at/vTY6i #GlobalBiosimilarsWeek #GBW2026

We are presenting clinical and scientific data for two of our biosimilars at the European Society for Medical Oncology (ESMO) Congress 2026, highlighting our growing oncology portfolio. 🔗 Read the press release for more details: shorturl.at/N2Til

Small differences can occur between production batches of the same biologic, also known as #BatchToBatchVariability. All living cells naturally vary from each other. Discover how high similarity is achieved for biosimilars despite this in our latest #BiosimilarsExplained.

Biosimilars are helping more patients access biologic treatments sooner. Between 2019 and 2024, biosimilar treatment days per 100,000 people in Europe more than doubled. Learn more in this @rapporteur_news article: shorturl.at/lCJvO #BiosimilarsInEurope

Arthritis is not a single condition, but an umbrella term for more than 100 conditions that affect the joints. We remain committed to broadening access to high-quality biologic medicines that help to support quality of life for several forms of arthritis. #WorldArthritisDay

Thomas Newcomer, SVP and Head of US Commercial at Samsung Bioepis, discusses advancing biosimilar adoption in the US during his fireside chat at @STAT’s virtual event, “Biosimilars: Have We Reached an Inflection Point?” Watch the highlights for more insights.

Can you confidently say you #LoveYourEyes? #WorldSightDay reminds us to be proactive: take regular breaks from screens, pay attention to changes in vision, and schedule regular eye checkups.

Complex health topics can create barriers to health literacy. Resources like our #BiosimilarsExplained series help foster informed conversations around treatment access. Explore the first edition of Biosimilars Explained: lnkd.in/p/geT7ydar #HealthLiteracyMonth

Joseph Park, our Senior Manager, Regulatory Strategy and Policy, External Operations, presents “Analytical Assurance in the New Era of Streamlined Biosimilar Development” at the Festival of Biologics Basel 2026 on October 15. 🔗 See the agenda: shorturl.at/GiB1v

Knowing your body makes it easier to detect differences and seek timely treatment. Recommendations for breast cancer screening can vary, but spotting an abnormality can start with regular breast self-exams.

Our development, licensing, and commercialization partnership with Teva Pharmaceuticals covers two new immunology biosimilar candidates in global markets, including the US, Europe, and Canada. Read the press release: shorturl.at/AZtK6

Real-world evidence on our ophthalmology biosimilar is heading to @EURETINA 2026, featured in an e-poster with interim results from a large post-marketing study that reinforce clinical confidence in its use. Learn more: shorturl.at/mNJgi